Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

Coiffier, Bertrand; Thiéblemont, Catherine; Van Den Neste, Éric; Lepeu, G.; Plantier, Isabelle; Castaigné, Sylvie; Lefort, Sophie; Marit, Gérald; Macro, Margaret; Sebban, Catherine; Belhadj, Karim; Bordessoule, Dominique; Fermé, Christophe; Tilly, Hervé

doi:10.1182/blood-2010-03-276246

Public

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

Published in Blood • Jun 15, 2010

Authors:

Bertrand Coiffier

Catherine Thiéblemont

Éric Van Den Neste

Abstract

We report the outcome of patients included in the LNH-98.5 study, which compared cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) to rituximab plus CHOP (R-CHOP) therapy in 399 patients with diffuse large B-cell lymphoma (DLBCL) aged 60 to 80 years, with a median follow-up time of 1...

Subject

Medicine

Rituximab

CHOP

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!